Compare EHC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHC | RDY |
|---|---|---|
| Founded | 1983 | 1984 |
| Country | United States | India |
| Employees | N/A | 27527 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.9B |
| IPO Year | 1994 | 2001 |
| Metric | EHC | RDY |
|---|---|---|
| Price | $102.30 | $14.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $143.29 | $16.90 |
| AVG Volume (30 Days) | 830.8K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.74% | 0.52% |
| EPS Growth | ★ 24.22 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.33 | $7.72 |
| Revenue Next Year | $8.14 | $3.50 |
| P/E Ratio | $51.76 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $92.77 | $12.19 |
| 52 Week High | $127.99 | $15.25 |
| Indicator | EHC | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 71.46 |
| Support Level | $99.36 | $13.80 |
| Resistance Level | $108.96 | $14.93 |
| Average True Range (ATR) | 3.05 | 0.23 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 67.87 | 98.97 |
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.